Summary & Overview
CPT 90380: RSV Monoclonal Antibody, 0.5 mL Intramuscular Dose
CPT code 90380 designates a monoclonal antibody administered intramuscularly to provide seasonal protection against respiratory syncytial virus (RSV). As a targeted passive immunoprophylaxis product delivered as a 0.5 mL dose, this code is relevant for outpatient immunization services, particularly in pediatric and high-risk adult populations during RSV season. Nationally, use of RSV monoclonal antibodies has implications for prevention strategies, supply management, and payer coverage policies.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for 90380, typical sites of service, and the service type. The publication summarizes coverage considerations, common billing modifiers, and where data was available or not. It also outlines benchmark and policy topics relevant to payers and providers, helping stakeholders understand how 90380 fits into seasonal immunization workflows and claim submission practices.
What readers will learn: clinical description and intended use of the product coded by 90380, which payers are included in the coverage review, and a summary of the types of benchmarks and policy updates typically relevant to seasonal monoclonal antibody immunizations. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 90380 represents a monoclonal antibody product administered intramuscularly to provide passive protection against respiratory syncytial virus (RSV). The product is supplied as a seasonal dose with a volume of 0.5 mL.
Service type: Immunization / Passive Immunoprophylaxis
Typical site of service: Outpatient clinic or ambulatory care setting, including pediatric clinics and specialized immunization centers.
Clinical & Coding Specifications
Clinical Context
A full-term or preterm infant or high-risk pediatric patient presents during RSV season for administration of passive immunoprophylaxis. The patient is scheduled for a single intramuscular injection of a monoclonal antibody product, 0.5 mL dose, to provide protection against respiratory syncytial virus (RSV). Typical settings include outpatient pediatric clinics, primary care offices, community health centers, and hospital-based outpatient infusion or immunization clinics. The clinical workflow includes verification of patient eligibility and dosing history, informed consent from the parent or guardian, review of allergies and prior adverse reactions, preparation of the 0.5 mL intramuscular dose, administration into the anterolateral thigh for infants or deltoid for older children, observation for acute adverse reactions for 15–30 minutes, documentation of lot number and expiration, and billing using 90380 for the seasonal intramuscular monoclonal antibody RSV prophylaxis dose. Common payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage adjudication and benefit verification prior to service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default unmodified code | Use when no modifier applies and service is billed routinely. |